Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc. (Marinus) is a privately held specialty pharmaceutical company. It is engaged in reformulation, development, and commercialization of innovative therapeutics for the treatment of serious disorders in the areas of neurology, psychiatry, and pain. Currently, the company develops a novel compound that targets CNS indications such as catamenial seizures, posttraumatic stress disorder and postpartum depression. It develops Ganaxolone, a synthetic neurosteroid for the treatment of refractory epilepsy and partial complex seizures under Phase 2b clinical development. Marinus undertakes its research and development operations extensively and entered into a partnership with Purdue Pharma L.P., Yale University and The Epilepsy Foundation of the US to expand the scope of its research and development operations. Key investors in the company include, Domain Associates, Sofinnova Ventures, Canaan Partners, and Foundation Medical Partners. The company is headquartered in Branford, Connecticut, the US.

Street: 
21 Business Park Drive
City: 
Branford
Postcode: 
06405
Federal State : 
United States
WebSite: 
www.marinuspharma.com
Fax: 
1-203-3150565

Company Index Score

Current Index Score Historical Index Score
  • Marinus Pharmaceuticals, Inc. currently scores 50 % in the index.
  • Marinus Pharmaceuticals, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Marinus Pharmaceuticals, Inc. is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets